Clean Bill of Health: Marksans Pharma’s US FDA Inspection Yields Zero Observations

Marksans Pharma Ltd successfully concluded the US FDA’s CGMP inspection at its Goa manufacturing facility with zero observations. This achievement underscores the company’s commitment to compliance, quality manufacturing, and global regulatory standards, enhancing its reputation and strengthening its position in the competitive pharmaceutical export market.

Show more

Stay Ahead – Explore Now! India Pursues Multi-Sector Trade Deal with US Ahead of April Tariff Deadline